Neuronetics (STIM)
(Delayed Data from NSDQ)
$0.91 USD
+0.05 (5.81%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.91 USD
+0.05 (5.81%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Zacks News
Walgreens Boots (WBA) Gains From New Alliances Amid Macro Woes
by Zacks Equity Research
Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.
Neogen (NEOG) Introduces 2 Assays for Histamine Detection
by Zacks Equity Research
Neogen (NEOG) launches Reveal for Histamine and Reveal Q+ for Histamine assays for the detection of Histamine.
LabCorp (LH) Expands Precision Oncology With Biopsy Test
by Zacks Equity Research
The addition of Labcorp Plasma Focus marks a pivotal step in the expansion of LabCorp's (LH) suite of precision oncology tests.
Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23
by Zacks Equity Research
At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.
Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Revised)
by Zacks Equity Research
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio
by Zacks Equity Research
Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.
Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome
by Zacks Equity Research
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.
Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays
by Zacks Equity Research
Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.
Illumina (ILMN) Progresses in Pathogen Genomic Technologies
by Zacks Equity Research
Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.
Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo
by Zacks Equity Research
Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.
Integra (IART) Builds Advanced R&D Facility in New Jersey
by Zacks Equity Research
Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 2.56% and 2.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 30.23% and 9.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
5 Winning Medical Product Stocks That Still Have Room to Run
by Indrajit Bandyopadhyay
Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.
Is Neuronetics (STIM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Neuronetics (STIM) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Neuronetics (STIM) Is Up 12.75% in One Week: What You Should Know
by Zacks Equity Research
Does Neuronetics (STIM) have what it takes to be a top stock pick for momentum investors? Let's find out.
New Strong Buy Stocks for November 16th
by Zacks Equity Research
ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.
Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 36.36% and 11.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 200% and 0.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 15.09% and 4.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 16.67% and 2.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 9.30% and 6.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.